Moneycontrol
Get App
Last Updated : Jan 17, 2017 04:48 PM IST | Source: Moneycontrol.com

Alembic Pharma Q3 PAT may dip 16% to Rs 100 cr: HDFC Securities

Net Sales are expected to decrease by 9.5 percent Q-o-Q (down 14.2 percent Y-o-Y) to Rs 790 crore, according to HDFC Securities.

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

HDFC Securities has come out with its third quarter (October-December) earnings estimates for the Pharmaceuticals sector. The brokerage house expects Alembic Pharma to report net profit at Rs 100 crore down 16.1% quarter-on-quarter.


Net Sales are expected to decrease by 9.5 percent Q-o-Q (down 14.2 percent Y-o-Y) to Rs 790 crore, according to HDFC Securities.


Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to fall by 12 percent Q-o-Q (down 59.3 percent Y-o-Y) to Rs 160 crore.


Disclaimer:
The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.


Exclusive offer: Use code "BUDGET2020" and get Moneycontrol Pro's Subscription for as little as Rs 333/- for the first year.

First Published on Jan 17, 2017 04:22 pm
Sections
Follow us on